Needham analyst Mike Matson reiterates Paragon 28 (NYSE:FNA) with a Buy and maintains $24 price target.
Benchmark Initiates Coverage On Biofrontera with Buy Rating, Announces Price Target of $11
Benchmark analyst Bruce Jackson initiates coverage on Biofrontera (NASDAQ:BFRI) with a Buy rating and announces Price Target of $11.